Safety and efficacy of faecal microbiota transplantation in patients with acute uncomplicated diverticulitis: study protocol for a randomised placebo-controlled trial

被引:0
|
作者
Thorndal, Camilla [1 ]
Kragsnaes, Maja Skov [2 ,3 ]
Nilsson, Anna Christine [4 ]
Holm, Dorte Kinggaard [4 ]
Christensen, Rene dePont [5 ]
Ellingsen, Torkell [2 ,3 ]
Kjeldsen, Jens [2 ,6 ]
Bjorsum-Meyer, Thomas [1 ]
机构
[1] Odense Univ Hosp, Dept Surg, Baagoes Alle 15, DK-5000 Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[3] Odense Univ Hosp, Dept Rheumatol, Odense, Denmark
[4] Odense Univ Hosp, Dept Clin Immunol, Odense, Denmark
[5] Univ Southern Denmark, Dept Publ Hlth, Res Unit Gen Practice, Copenhagen, Denmark
[6] Odense Univ Hosp, Dept Med Gastrointestinal Dis, Odense, Denmark
关键词
acute uncomplicated diverticulitis; faecal microbiota transplantation; placebo; randomised controlled trial; CLOSTRIDIUM-DIFFICILE INFECTION; GUT MICROBIOTA; MEDICAL-MANAGEMENT; MOLECULAR ANALYSIS; DISEASE; RECURRENT; RISK; HOSPITALIZATION; METAANALYSIS; GUIDELINES;
D O I
10.1177/17562848241309868
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Little is known about the involvement of gut microbiota in the disease course of diverticulitis and the potential benefits of manipulating the gut milieu. We propose to conduct a randomised placebo-controlled feasibility trial of faecal microbiota transplantation (FMT) given as capsules to patients with acute uncomplicated diverticulitis.Objectives: The objective is primarily to investigate the feasibility of clinical safety, explore efficacy associated with FMT in this patient population, and examine changes in patient-reported quality of life and the composition and function of the gut microbiota.Design: Study protocol for a randomised placebo-controlled trial.Methods and analysis: Participants with acute, uncomplicated diverticulitis, as confirmed by computed tomography (CT) scan, will be recruited from Odense University Hospital (Denmark) and randomly assigned to either the intervention group or the control group. The intervention group will consist of 20 patients who receive encapsulated FMT. The control group will also consist of 20 patients, receiving placebo capsules. Primary safety endpoint: Patient safety is monitored by (a) the number of re-admissions and (b) the number of adverse events within 3 months of FMT/placebo; Primary efficacy endpoint: Reduction in the proportion of patients treated with antibiotics within 3 months following FMT/placebo; Secondary outcome: Change from baseline to 3 months in the GI-QLI questionnaire. Results will be analysed using an intention-to-treat approach. Adverse events or unintended consequences will be reported.Ethics and discussion: This is the first study to investigate the safety and efficacy of FMT in patients with acute uncomplicated diverticulitis. The project has the potential to broaden the knowledge and literature on the role of the intestinal microbiota in diverticulitis, and we believe it will elevate our understanding of cause and effect.Trial registration: Informed consent is obtained from all participants. The study is approved by the regional ethics committee (ref. S-20230023) and the Danish Data Protection Agency (ref. 24/2435). The trial was registered on clinicaltrials.gov (NCT06254625) on 10th February 2024.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial
    Kragsnaes, Maja Skov
    Kjeldsen, Jens
    Horn, Hans Christian
    Munk, Heidi Lausten
    Pedersen, Jens Kristian
    Just, Soren Andreas
    Ahlquist, Palle
    Pedersen, Finn Moeller
    de Wit, Maarten
    Moller, Soren
    Andersen, Vibeke
    Kristiansen, Karsten
    Holm, Dorte Kinggaard
    Holt, Hanne Marie
    Christensen, Robin
    Ellingsen, Torkell
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (09) : 1158 - 1167
  • [2] Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial
    Kragsnaes, Maja Skov
    Kjeldsen, Jens
    Horn, Hans Christian
    Munk, Heidi Lausten
    Pedersen, Finn Moeller
    Holt, Hanne Marie
    Pedersen, Jens Kristian
    Holm, Dorte Kinggaard
    Glerup, Henning
    Andersen, Vibeke
    Fredberg, Ulrich
    Kristiansen, Karsten
    Christensen, Robin
    Ellingsen, Torkell
    BMJ OPEN, 2018, 8 (04):
  • [3] Efficacy and Safety of Faecal Microbiota Transplantation for Acute Pancreatitis: A Randomised, Controlled Study
    Ding, Ling
    He, Cong
    Li, Xueyang
    Huang, Xin
    Lei, Yupeng
    Ke, Huajing
    Chen, Hongyan
    Yang, Qinyu
    Cai, Yan
    Liao, Yuanhang
    He, Wenhua
    Xia, Liang
    Xiong, Huifang
    Lu, Nonghua
    Zhu, Yin
    FRONTIERS IN MEDICINE, 2022, 8
  • [4] Correspondence on 'Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial'
    McGonagle, Dennis G.
    Bridgewood, Charlie
    Marzo-Ortega, Helena
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (07)
  • [5] Protocol for a randomised, placebo-controlled pilot study for assessing feasibility and efficacy of faecal microbiota transplantation in a paediatric ulcerative colitis population: PediFETCh trial
    Pai, Nikhil
    Popov, Jelena
    BMJ OPEN, 2017, 7 (08):
  • [6] Cirrhosis and Faecal microbiota Transplantation (ChiFT) protocol: a Danish multicentre, randomised, placebo-controlled trial in patients with decompensated liver cirrhosis
    Stoy, Sidsel
    Eriksen, Lotte Lindgreen
    Lauszus, Johanne Sloth
    Damsholt, Soren
    Baunwall, Simon Mark Dahl
    Erikstrup, Christian
    Vilstrup, Hendrik
    Jepsen, Peter
    Hvas, Christian
    Thomsen, Karen Louise
    BMJ OPEN, 2025, 15 (02):
  • [7] FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial
    Al-Shakhshir, Sarah
    Quraishi, Mohammed Nabil
    Mullish, Benjamin
    Patel, Arzoo
    Vince, Alexandra
    Rowe, Anna
    Homer, Victoria
    Jackson, Nicola
    Gyimah, Derick
    Shabir, Sahida
    Manzoor, Susan
    Cooney, Rachel
    Alrubaiy, Laith
    Quince, Christopher
    van Schaik, Willem
    Hares, Miriam
    Beggs, Andrew D.
    Efstathiou, Elena
    Rimmer, Peter
    Weston, Chris
    Iqbal, Tariq
    Trivedi, Palak J.
    BMJ OPEN, 2025, 15 (01):
  • [8] Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study
    El-Salhy, Magdy
    Hatlebakk, Jan Gunnar
    Gilja, Odd Helge
    Kristoffersen, Anja Brathen
    Hausken, Trygve
    GUT, 2020, 69 (05) : 859 - 867
  • [9] FTACMT study protocol: a multicentre, double-blind, randomised, placebo-controlled trial of faecal microbiota transplantation for autism spectrum disorder
    Ye Chen
    Zhang Xueying
    Cui Jiaqu
    Chen Qiyi
    Qin Huanlong
    Li Ning
    Du Yasong
    Zhao Xiaoxin
    Yang Rong
    Lu Jubao
    Lv Xiaoqiong
    Ma Chunlian
    Wang Yu
    Chen Shidong
    Kuang Guifang
    Zhao Dongmei
    Fang Shuanfeng
    Zhang Xujing
    Yang Binrang
    Wang Yanxia
    Li Ling
    Yuan Song
    Zhou Xiang
    Zhang Beihua
    Jiang Lin
    Ji Hong
    BMJ OPEN, 2022, 12 (01):
  • [10] Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial
    Paramsothy, Sudarshan
    Kamm, Michael A.
    Kaakoush, Nadeem O.
    Walsh, Alissa J.
    van den Bogaerde, Johan
    Samuel, Douglas
    Leong, Rupert W. L.
    Connor, Susan
    Ng, Watson
    Paramsothy, Ramesh
    Xuan, Wei
    Lin, Enmoore
    Mitchell, Hazel M.
    Borody, Thomas J.
    LANCET, 2017, 389 (10075): : 1218 - 1228